t5 caption a7 algorithms Search Results


t5 caption a7 microrna lna pcr primer id microrna lna pcr primer id cel mir 39 3p yp00203952  (Thermo Fisher)
90
Thermo Fisher t5 caption a7 microrna lna pcr primer id microrna lna pcr primer id cel mir 39 3p yp00203952
List of <t> microRNA </t> primers (Qiagen GmbH, Germany)
T5 Caption A7 Microrna Lna Pcr Primer Id Microrna Lna Pcr Primer Id Cel Mir 39 3p Yp00203952, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t5 caption a7 microrna lna pcr primer id microrna lna pcr primer id cel mir 39 3p yp00203952/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
t5 caption a7 microrna lna pcr primer id microrna lna pcr primer id cel mir 39 3p yp00203952 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
t5 caption a7 rs12041331 placebo aspirin total gg 5 630  (Thermo Fisher)
90
Thermo Fisher t5 caption a7 rs12041331 placebo aspirin total gg 5 630
Schematic overview (graphical abstract). We examined the relationship between <t>rs12041331</t> genotypes and cardiovascular and bleeding events in a randomized placebo-controlled study population of 13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Participants had no previous diagnosis of atherothrombotic cardiovascular disease (CVD) at enrollment, and were randomized to either 100 mg daily low-dose aspirin or placebo for a median 4.7 years of follow-up. End points analyzed included the primary CVD end point in the ASPREE study, and composites of major adverse cardiovascular events (MACE) and ischemic stroke; and bleeding events, including major hemorrhage and intracranial bleeding. Details of ASPREE end points are described previously.21 The modifying effect of the rs12041331-A genotype on association with cardiovascular and bleeding events and aspirin treatment was analyzed using an interaction term in a multivariable Cox regression model.
T5 Caption A7 Rs12041331 Placebo Aspirin Total Gg 5 630, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/t5 caption a7 rs12041331 placebo aspirin total gg 5 630/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
t5 caption a7 rs12041331 placebo aspirin total gg 5 630 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
gardasil  (Merck & Co)
90
Merck & Co gardasil
Characteristics of HPV VLP vaccines.
Gardasil, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gardasil/product/Merck & Co
Average 90 stars, based on 1 article reviews
gardasil - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


List of microRNA primers (Qiagen GmbH, Germany)

Journal: Physiological Research

Article Title: The Severity of Muscle Performance Deterioration in Sarcopenia Correlates With Circulating Muscle Tissue-Specific miRNAs

doi: 10.33549/physiolres.934778

Figure Lengend Snippet: List of microRNA primers (Qiagen GmbH, Germany)

Article Snippet: The PCR reaction was performed in a StepOnePlus Real-Time PCR System (Life Technologies, USA). lists the PCR primers used in this study. table ft1 table-wrap mode="anchored" t5 caption a7 microRNA LNA PCR primer ID microRNA LNA PCR primer ID cel-miR-39-3p YP00203952 hsa-miR-133a-3p YP00204788 hsa-miR-1-3p YP00204344 hsa-miR-133b YP00206058 hsa-miR-206 YP00206073 hsa-miR-208b-3p YP00204636 hsa-miR-29a-3p YP00204698 hsa-miR-499-5p YP00205935 hsa-miR-29b-3p YP00204679 Open in a separate window List of microRNA primers (Qiagen GmbH, Germany) Statistical analysis Statistical evaluation was performed by Graphpad using one way ANOVA test and Chi test.

Techniques:

Schematic overview (graphical abstract). We examined the relationship between rs12041331 genotypes and cardiovascular and bleeding events in a randomized placebo-controlled study population of 13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Participants had no previous diagnosis of atherothrombotic cardiovascular disease (CVD) at enrollment, and were randomized to either 100 mg daily low-dose aspirin or placebo for a median 4.7 years of follow-up. End points analyzed included the primary CVD end point in the ASPREE study, and composites of major adverse cardiovascular events (MACE) and ischemic stroke; and bleeding events, including major hemorrhage and intracranial bleeding. Details of ASPREE end points are described previously.21 The modifying effect of the rs12041331-A genotype on association with cardiovascular and bleeding events and aspirin treatment was analyzed using an interaction term in a multivariable Cox regression model.

Journal: Clinical pharmacology and therapeutics

Article Title: Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population

doi: 10.1002/cpt.1959

Figure Lengend Snippet: Schematic overview (graphical abstract). We examined the relationship between rs12041331 genotypes and cardiovascular and bleeding events in a randomized placebo-controlled study population of 13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Participants had no previous diagnosis of atherothrombotic cardiovascular disease (CVD) at enrollment, and were randomized to either 100 mg daily low-dose aspirin or placebo for a median 4.7 years of follow-up. End points analyzed included the primary CVD end point in the ASPREE study, and composites of major adverse cardiovascular events (MACE) and ischemic stroke; and bleeding events, including major hemorrhage and intracranial bleeding. Details of ASPREE end points are described previously.21 The modifying effect of the rs12041331-A genotype on association with cardiovascular and bleeding events and aspirin treatment was analyzed using an interaction term in a multivariable Cox regression model.

Article Snippet: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. a Self-reported. caption a8 Characteristics of genotyped participants by treatment status table ft1 table-wrap mode="anchored" t5 caption a7 rs12041331 Placebo Aspirin Total GG 5,630 (82.7%) 5,647 (83.8%) 11,277 (83.2%) GA 1,112 (16.3%) 1,034 (15.3%) 2,146 (15.8%) AA 64 (0.9%) 60 (0.9%) 124 (0.9%) 6,806 6,741 13,547 Open in a separate window Genomewide single-nucleotide polymorphism genotyping of 14,177 samples collected by the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research Array (Thermo Fisher Scientific) following standard protocols.

Techniques: Biomarker Discovery

Association of rs12041331 genotypes with ASPREE CVD and bleeding events in aspirin and placebo treatment groups

Journal: Clinical pharmacology and therapeutics

Article Title: Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population

doi: 10.1002/cpt.1959

Figure Lengend Snippet: Association of rs12041331 genotypes with ASPREE CVD and bleeding events in aspirin and placebo treatment groups

Article Snippet: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. a Self-reported. caption a8 Characteristics of genotyped participants by treatment status table ft1 table-wrap mode="anchored" t5 caption a7 rs12041331 Placebo Aspirin Total GG 5,630 (82.7%) 5,647 (83.8%) 11,277 (83.2%) GA 1,112 (16.3%) 1,034 (15.3%) 2,146 (15.8%) AA 64 (0.9%) 60 (0.9%) 124 (0.9%) 6,806 6,741 13,547 Open in a separate window Genomewide single-nucleotide polymorphism genotyping of 14,177 samples collected by the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research Array (Thermo Fisher Scientific) following standard protocols.

Techniques:

Cumulative incidence curves (additive genetic model). We undertook cumulative incidence analysis of cardiovascular and bleeding events in aspirin and placebo groups, stratified by rs12041331 genotypes using an additive model of genetic inheritance; GG wild type (blue curves), AG heterozygotes (red curves), and AA homozygotes (yellow curves). Events analyzed included the primary cardiovascular disease (CVD) end point in the ASPirin in Reducing Events in the Elderly (ASPREE) study (a, b), and composites of major adverse cardiovascular events (MACE) (c, d) and ischemic stroke (STROKE) (e, f); and the ASPREE clinically significant bleeding end point subcomponents of major hemorrhage (MHEM) (g, h) and intracranial bleeding (ICB) (i, j).

Journal: Clinical pharmacology and therapeutics

Article Title: Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population

doi: 10.1002/cpt.1959

Figure Lengend Snippet: Cumulative incidence curves (additive genetic model). We undertook cumulative incidence analysis of cardiovascular and bleeding events in aspirin and placebo groups, stratified by rs12041331 genotypes using an additive model of genetic inheritance; GG wild type (blue curves), AG heterozygotes (red curves), and AA homozygotes (yellow curves). Events analyzed included the primary cardiovascular disease (CVD) end point in the ASPirin in Reducing Events in the Elderly (ASPREE) study (a, b), and composites of major adverse cardiovascular events (MACE) (c, d) and ischemic stroke (STROKE) (e, f); and the ASPREE clinically significant bleeding end point subcomponents of major hemorrhage (MHEM) (g, h) and intracranial bleeding (ICB) (i, j).

Article Snippet: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. a Self-reported. caption a8 Characteristics of genotyped participants by treatment status table ft1 table-wrap mode="anchored" t5 caption a7 rs12041331 Placebo Aspirin Total GG 5,630 (82.7%) 5,647 (83.8%) 11,277 (83.2%) GA 1,112 (16.3%) 1,034 (15.3%) 2,146 (15.8%) AA 64 (0.9%) 60 (0.9%) 124 (0.9%) 6,806 6,741 13,547 Open in a separate window Genomewide single-nucleotide polymorphism genotyping of 14,177 samples collected by the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research Array (Thermo Fisher Scientific) following standard protocols.

Techniques:

Cumulative incidence curves (dominant genetic model). We undertook cumulative incidence analysis of cardiovascular and bleeding events in aspirin and placebo groups, stratified by rs12041331 genotypes using a dominant model of genetic inheritance; GG wild type (blue curves) vs. AG/AA carriers (red curves). Events analyzed included the primary cardiovascular disease (CVD) end point in the ASPirin in Reducing Events in the Elderly (ASPREE) study (a, b), and composites of major adverse cardiovascular events (MACEs) (c, d) and ischemic stroke (STROKE) (e, f); and the ASPREE clinically significant bleeding end point subcomponents of major hemorrhage (MHEM) (g, h) and intracranial bleeding (ICB) (I, j).

Journal: Clinical pharmacology and therapeutics

Article Title: Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population

doi: 10.1002/cpt.1959

Figure Lengend Snippet: Cumulative incidence curves (dominant genetic model). We undertook cumulative incidence analysis of cardiovascular and bleeding events in aspirin and placebo groups, stratified by rs12041331 genotypes using a dominant model of genetic inheritance; GG wild type (blue curves) vs. AG/AA carriers (red curves). Events analyzed included the primary cardiovascular disease (CVD) end point in the ASPirin in Reducing Events in the Elderly (ASPREE) study (a, b), and composites of major adverse cardiovascular events (MACEs) (c, d) and ischemic stroke (STROKE) (e, f); and the ASPREE clinically significant bleeding end point subcomponents of major hemorrhage (MHEM) (g, h) and intracranial bleeding (ICB) (I, j).

Article Snippet: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. a Self-reported. caption a8 Characteristics of genotyped participants by treatment status table ft1 table-wrap mode="anchored" t5 caption a7 rs12041331 Placebo Aspirin Total GG 5,630 (82.7%) 5,647 (83.8%) 11,277 (83.2%) GA 1,112 (16.3%) 1,034 (15.3%) 2,146 (15.8%) AA 64 (0.9%) 60 (0.9%) 124 (0.9%) 6,806 6,741 13,547 Open in a separate window Genomewide single-nucleotide polymorphism genotyping of 14,177 samples collected by the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research Array (Thermo Fisher Scientific) following standard protocols.

Techniques:

Tests of interaction effect between treatment group and the rs12041331-A genotype on ASPREE CVD and bleeding events

Journal: Clinical pharmacology and therapeutics

Article Title: Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population

doi: 10.1002/cpt.1959

Figure Lengend Snippet: Tests of interaction effect between treatment group and the rs12041331-A genotype on ASPREE CVD and bleeding events

Article Snippet: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. a Self-reported. caption a8 Characteristics of genotyped participants by treatment status table ft1 table-wrap mode="anchored" t5 caption a7 rs12041331 Placebo Aspirin Total GG 5,630 (82.7%) 5,647 (83.8%) 11,277 (83.2%) GA 1,112 (16.3%) 1,034 (15.3%) 2,146 (15.8%) AA 64 (0.9%) 60 (0.9%) 124 (0.9%) 6,806 6,741 13,547 Open in a separate window Genomewide single-nucleotide polymorphism genotyping of 14,177 samples collected by the ASPirin in Reducing Events in the Elderly (ASPREE) Healthy Ageing Biobank was performed using the Axiom 2.0 Precision Medicine Diversity Research Array (Thermo Fisher Scientific) following standard protocols.

Techniques:

Characteristics of HPV VLP vaccines.

Journal:

Article Title: An Update of Prophylactic Human Papillomavirus L1 Virus-Like Particle Vaccine Clinical Trial Results

doi: 10.1016/j.vaccine.2008.06.002

Figure Lengend Snippet: Characteristics of HPV VLP vaccines.

Article Snippet: Both vaccines must be refrigerated and are administered by intramuscular injection in the deltoid area, but differ slightly in the timing of the second dose. table ft1 table-wrap mode="anchored" t5 caption a7 Gardasil® Cervarix® Manufacturer Merck GlaxoSmithKline VLP types −6/11/16/18 −16/18 Dose of L1 protein 20/40/40/20 µg 20/20 µg Producer cells Saccharomyces cerevisiae (bread yeast) expressing L1 Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus Adjuvant 225 µg aluminum hydroxyphosphate sulfate 500 µg aluminum hydroxide, 50 µg 3-O-deacylated-4’- monophosphoryl lipid A Injection schedule 0, 2, 6 months 0, 1, 6 months Open in a separate window VLP: Virus-like particle.

Techniques: Expressing, Infection, Recombinant, Injection

Outline of vaccine efficacy trials in young women.

Journal:

Article Title: An Update of Prophylactic Human Papillomavirus L1 Virus-Like Particle Vaccine Clinical Trial Results

doi: 10.1016/j.vaccine.2008.06.002

Figure Lengend Snippet: Outline of vaccine efficacy trials in young women.

Article Snippet: Both vaccines must be refrigerated and are administered by intramuscular injection in the deltoid area, but differ slightly in the timing of the second dose. table ft1 table-wrap mode="anchored" t5 caption a7 Gardasil® Cervarix® Manufacturer Merck GlaxoSmithKline VLP types −6/11/16/18 −16/18 Dose of L1 protein 20/40/40/20 µg 20/20 µg Producer cells Saccharomyces cerevisiae (bread yeast) expressing L1 Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus Adjuvant 225 µg aluminum hydroxyphosphate sulfate 500 µg aluminum hydroxide, 50 µg 3-O-deacylated-4’- monophosphoryl lipid A Injection schedule 0, 2, 6 months 0, 1, 6 months Open in a separate window VLP: Virus-like particle.

Techniques: Infection

Prophylactic efficacy of VLP vaccines against infection and lesions related to vaccine targeted HPV types.

Journal:

Article Title: An Update of Prophylactic Human Papillomavirus L1 Virus-Like Particle Vaccine Clinical Trial Results

doi: 10.1016/j.vaccine.2008.06.002

Figure Lengend Snippet: Prophylactic efficacy of VLP vaccines against infection and lesions related to vaccine targeted HPV types.

Article Snippet: Both vaccines must be refrigerated and are administered by intramuscular injection in the deltoid area, but differ slightly in the timing of the second dose. table ft1 table-wrap mode="anchored" t5 caption a7 Gardasil® Cervarix® Manufacturer Merck GlaxoSmithKline VLP types −6/11/16/18 −16/18 Dose of L1 protein 20/40/40/20 µg 20/20 µg Producer cells Saccharomyces cerevisiae (bread yeast) expressing L1 Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus Adjuvant 225 µg aluminum hydroxyphosphate sulfate 500 µg aluminum hydroxide, 50 µg 3-O-deacylated-4’- monophosphoryl lipid A Injection schedule 0, 2, 6 months 0, 1, 6 months Open in a separate window VLP: Virus-like particle.

Techniques: Infection

Immunogenicity bridging studies.

Journal:

Article Title: An Update of Prophylactic Human Papillomavirus L1 Virus-Like Particle Vaccine Clinical Trial Results

doi: 10.1016/j.vaccine.2008.06.002

Figure Lengend Snippet: Immunogenicity bridging studies.

Article Snippet: Both vaccines must be refrigerated and are administered by intramuscular injection in the deltoid area, but differ slightly in the timing of the second dose. table ft1 table-wrap mode="anchored" t5 caption a7 Gardasil® Cervarix® Manufacturer Merck GlaxoSmithKline VLP types −6/11/16/18 −16/18 Dose of L1 protein 20/40/40/20 µg 20/20 µg Producer cells Saccharomyces cerevisiae (bread yeast) expressing L1 Trichoplusia ni (Hi 5) insect cell line infected with L1 recombinant baculovirus Adjuvant 225 µg aluminum hydroxyphosphate sulfate 500 µg aluminum hydroxide, 50 µg 3-O-deacylated-4’- monophosphoryl lipid A Injection schedule 0, 2, 6 months 0, 1, 6 months Open in a separate window VLP: Virus-like particle.

Techniques: Serologic Assay, Blocking Assay, Enzyme-linked Immunosorbent Assay